Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

NDRG2 Expression Increases Apoptosis Induced by Doxorubicin in Malignant Breast Caner Cells

  • Kim, Myung-Jin (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University) ;
  • Kang, Kyeong-Ah (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University) ;
  • Yang, Young (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University) ;
  • Lim, Jong-Seok (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

N-myc downstream-regulated gene 2 (NDRG2) has recently been found to be a tumor suppressor gene. Although it has been reported that NDRG2 expression in breast cancer cells decreases cell proliferation by inhibiting STAT3 activation via SOCS1 induction, the molecular mechanism of chemotherapeutic agent-induced apoptosis is not well known. To elucidate the effect of NDRG2 on the apoptotic pathway induced by doxorubicin, we established stable cell lines expressing NDRG2 and investigated the effect of NDRG2 expression on the doxorubicin-induced apoptosis. While STAT3 activation was remarkably inhibited by NDRG2 overexpression, the expression level of p21 was increased by NDRG2 expression. We confirmed that NDRG2-expressing cells treated with doxorubicin suppressed STAT3 activation and upregulated p21 expression. NDRG2 expression considerably enhanced TUNEL positive apoptotic cells, poly-ADP ribose polymerase (PARP) cleavage, release of cytochrome c to cytosol, and caspase-3 activity in doxorubicin-induced apoptosis. Bid expression in a resting state and after treatment with doxorubicin increased in MDA-MB-231-NDRG2 cells compared to MDA-MB-231-mock cells. Meanwhile, Bcl-$x_L$ expression decreased in MDA-MB-231-NDRG2 cells compared to MDA-MB-231-mock cells in a resting state and in doxorubicin-treated cells. Collectively, these data suggest that suppression of STAT3 activation by NDRG2 influences the sensitivity to doxorubicin-induced apoptosis of breast cancer cells and this may provide a potential therapeutic benefit to overcome the resistance against doxorubicin in breast cancer.

Keywords

References

  1. Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., Sung, B. and Ichikawa, H. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091, 151-169. https://doi.org/10.1196/annals.1378.063
  2. Choi, S. C., Yoon, S. R., Park, Y. P., Song, E. Y., Kim, J. W., Kim, W. H., Yang, Y., Lim, J. S. and Lee, H. G. (2007). Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 39, 705-714. https://doi.org/10.1038/emm.2007.77
  3. Costantino, L. and Barlocco, D. (2008). STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 15, 834-843. https://doi.org/10.2174/092986708783955464
  4. Decker, P. and Muller, S. (2002). Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotech. 3, 275-283. https://doi.org/10.2174/1389201023378265
  5. Deng, Y., Yao, L., Chau, L., Ng, S. S., Peng, Y., Liu, X., Au, W. S., Wang, J., Li, F., Ji, S., Han, H., Nie, X., Li, Q., Kung, H. F., Leung, S. Y. and Lin, M. C. (2003). N-Myc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer 106, 342-347. https://doi.org/10.1002/ijc.11228
  6. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R. and Loughran, T. P. Jr. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351- 362. https://doi.org/10.1172/JCI9940
  7. Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K. and Gewirtz, D. A. (1994). Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45, 649-656.
  8. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro- Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A. and Jove, R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513. https://doi.org/10.1038/sj.onc.1204349
  9. Gariboldi, M. B., Ravizza, R., Molteni, R., Osella, D., Gabano, E. and Monti, E. (2007). Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 258, 181-188. https://doi.org/10.1016/j.canlet.2007.08.019
  10. Ghobrial, I. M., Witzig, T. E. and Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194. https://doi.org/10.3322/canjclin.55.3.178
  11. Hu, X. L., Liu, X. P., Lin, S. X., Deng, Y. C., Liu, N., Li, X. and Yao, L. B. (2004). NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol. 10, 3518-3521. https://doi.org/10.3748/wjg.v10.i23.3518
  12. Ishii, Y., Waxman, S. and Germain, D. (2008). Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 68, 852-860. https://doi.org/10.1158/0008-5472.CAN-07-2879
  13. Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164. https://doi.org/10.1016/S0092-8674(02)00625-6
  14. Kim, Y. J., Yoon, S. Y., Kim, J. T., Choi, S. C., Lim, J. S., Kim, J. H., Song, E. Y., Lee, H. G., Choi, I. and Kim, J. W. (2008). NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer 124, 7-15. https://doi.org/10.1002/ijc.23945
  15. Lachat, P., Shaw, P., Gebhard, S., van Belzen, N., Chaubert, P. and Bosman, F. T. (2002). Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem. Cell Biol. 118, 399-408. https://doi.org/10.1007/s00418-002-0460-9
  16. Lui, N., Wang, L., Li, X., Yang, Q., Liu, X., Zhang, J., Zhang, J., Wu, Y., Ji, S., Zhang, Y., Yang, A., Han, H. and Yao, L. (2008). N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucl. Acid Res. 36, 5335-5349. https://doi.org/10.1093/nar/gkn504
  17. Lusis, E. A., Watson, M. A., Chicoine, M. R., Lyman, M., Roerig, P., Reifenberger, G., Gutmann, D. H. and Perry, A. (2005). Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65, 7121- 7126. https://doi.org/10.1158/0008-5472.CAN-05-0043
  18. Okuda, T. and Kondoh, H. (1999). Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. Biochem. Biophys. Res. Commun. 266, 208-215. https://doi.org/10.1006/bbrc.1999.1780
  19. Park, Y., Shon, S. K., Kim, A., Kim, K. I., Yang, Y., Cho, D. H., Lee, M. S. and Lim, J. S. (2007). SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem. Biophys. Res. Commun. 363, 361-367. https://doi.org/10.1016/j.bbrc.2007.08.195
  20. Qu, X., Zhai, Y., Wei, H., Zhang, C., Xing, G., Yu, Y. and He, F. (2002). Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 229, 35-44. https://doi.org/10.1023/A:1017934810825
  21. Swift, L. P., Cutts, S. M., Nudelman, A., Levovich, I., Rephaeli, A. and Phillips, D. R. (2008). The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 61, 739-749. https://doi.org/10.1007/s00280-007-0528-2
  22. Wang, Y. A., Johnson, S. K., Brown, B. L., McCarragher, L. M., Al-Sakkaf, K., Royds, J. A. and Dobson, P. R. (2008). Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int. J. Cancer 123, 1536-1544. https://doi.org/10.1002/ijc.23671
  23. Zhou, R. H., Kokame, K., Tsukamoto, Y., Yutani, C., Kato, H. and Miyata, T. (2001). Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73, 86-97. https://doi.org/10.1006/geno.2000.6496